Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Wpływ spożycia produktu testowego na oddawanie moczu u zdrowych dorosłych Japończyków

29 września 2026 zaktualizowane przez: Indena S.p.A

Wpływ spożycia produktu testowego na oddawanie moczu u zdrowych dorosłych Japończyków: randomizowane, kontrolowane placebo, podwójnie ślepe, równoległe badanie porównawcze

The goal of this clinical trial is to test in Japanese adults who experience concerns regarding urinary frequency. The main question it aims to answer is:

•Does consumption of Cranberry Phospholipids reduce daytime urinary frequency?

Participants will be given the following tasks:

  • Take two tablets daily containing Cranberry Phospholipid for eight weeks.
  • Answer the questionnaire on the overactive bladder (OAB)-specific quality of life (QOL).
  • Answer the questionnaire on OAB symptoms.
  • Answer the questionnaire on urinary frequency during the study period. Researchers will compare Cranberry Phospholipids and placebo groups to see if Cranberry Phospholipids reduces daytime urinary frequency.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Szacowany)

76

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Tokyo
      • Nerima-ku, Tokyo, Japonia, 176-0002
        • Rekrutacyjny
        • Nerima Medical Association Minami-machi Clinic
        • Kontakt:
        • Kontakt:
        • Główny śledczy:
          • Masafumi Nagata, MD
      • Shinagawa-Ku, Tokyo, Japonia, 141-0022
        • Rekrutacyjny
        • Medical Corporation Seishinkai, Takara Clinic
        • Kontakt:
        • Kontakt:
        • Główny śledczy:
          • Tsuyoshi Takara, MD

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Japanese
  • Men or women
  • Adults
  • Healthy individuals
  • Individuals with positive urine leukocytes at baseline
  • Individuals whose score of urinary urgency of overactive bladder symptom score (OABSS) is less than two or total score of OABSS is less than three at baseline
  • Individuals whose "frequent urination during the daytime hours" of "symptom bother" of OAB-q is relatively high at baseline

Exclusion Criteria:

  • Individuals undergoing medical treatment or having a medical history of malignant tumor, heart failure, or myocardial infarction
  • Individuals carrying a pacemaker or an implantable cardioverter defibrillator
  • Individuals undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
  • Individuals who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage as part of their daily diet
  • Individuals currently regularly taking medications (including herbal medicines) and supplements
  • Individuals who are allergic to medicines and/or the test-product-related products in this trial
  • Individuals with urinary pain
  • Individuals undergoing treatment, have had treatment within two months, or need the treatment for diseases related to urination, e.g. benign prostatic hypertrophy, prostatitis, prostate cancer, overactive bladder, hypoactive bladder, cystitis, interstitial cystitis, bladder cancer, bladder stones, urethritis, urethral stricture, neurological disease, polyuria, and nocturnal polyuria
  • Individuals have overactive bladder symptom (individuals who urinate eight times or more per day, and have urinary urgency at least once a week)
  • Individuals wake up twice or more to urinate at bedtime
  • Individuals are pregnant, breast-feeding, and planning to become pregnant
  • Individuals have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
  • Individuals are judged as ineligible to participate in the trial by the physician

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Inny
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Cranberry Phospholipids

Take two tablets (containing 120 mg cranberry phospholipids/tablet)

Take two tablets will be taken once daily

Komparator placebo: Placebo

Take two tablets (containing 0 mg cranberry phospholipids/tablet)

Take two tablets will be taken once daily

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Measured value for the Overactive Bladder Questionnaire (OAB-q) questionnaire item "frequent urination during the daytime hours" after the 8-week intervention
Ramy czasowe: After the 8-week intervention

Using OAB-q, we evaluate OAB-specific quality of life (QOL). The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL.

After the 8-week intervention

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Individuals whose the response to the OAB-q questionnaire item "frequent urination during the daytime hours" improved by one or more scale points after the 8-week intervention compared to Baseline
Ramy czasowe: Baseline, and after the 8-week intervention

Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL.

Baseline, and after the 8-week intervention
The amount of change, and percentage of change from Baseline for the OAB-q questionnaire item "frequent urination during the daytime hours" after the 8-week intervention
Ramy czasowe: Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention

Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL.

Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
The measured values, amount of changes, and percentage of changes from Baseline for all other questionnaire items of the OAB-q, excluding "frequent urination during the daytime hours," after the 8-week intervention
Ramy czasowe: Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention

Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL.

Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
The measured values, and amount of changes and percentage of changes from Period 1 for the average frequency of urination during the daytime, during the nighttime, and all day, as measured during Periods 2 to 9
Ramy czasowe: Period 1 (7 days prior to Baseline), Period 2~9 (periods separated by 7 days from the start of intervention)

Participants will maintain a daily diary of their urination frequency during two distinct periods: for 7 days immediately preceding the Baseline, and from the beginning of the intervention until the day before the final examination.

Period 1 (7 days prior to Baseline), Period 2~9 (periods separated by 7 days from the start of intervention)
Individuals who experienced adverse events
Ramy czasowe: After the 8-week intervention

During the trial period, if a participant exhibits any clinically significant "new manifestation of abnormality" or "aggravation" in his/her physical signs and symptoms, it is considered to be an adverse event.

After the 8-week intervention
Individuals whose values of urinalysis and peripheral blood test are outside the reference range after intervention despite within the reference range at Baseline
Ramy czasowe: Baseline, and after the 8-week intervention

The ratio of cases which had test items stated in urinalysis and peripheral blood examination within their respective standard ranges before intervention but exceeded the ranges after intervention are calculated, intergroup comparison at each time point is performed using tests for comparing proportions.

Baseline, and after the 8-week intervention
Body height
Ramy czasowe: Baseline, and after the 8-week intervention

Body height is measured using a height meter.

Baseline, and after the 8-week intervention
Body weight
Ramy czasowe: Baseline, and after the 8-week intervention

Body weight is measured using a body scale.

Baseline, and after the 8-week intervention
Blood pressure
Ramy czasowe: Baseline, and after the 8-week intervention

Systolic and diastolic blood pressure are measured using a digital wrist-type sphygmomanometer.

Baseline, and after the 8-week intervention
Urinalysis
Ramy czasowe: Baseline, and after the 8-week intervention

A urine sample (approximately 10 mL) will be collected from each participant, and the samples will be sent to LSI Medience Corporation for analysis.

Baseline, and after the 8-week intervention
Peripheral blood examination
Ramy czasowe: Baseline, and after the 8-week intervention

A venous blood sample (approximately 10 mL) will be collected from each participant, and the samples will be sent to LSI Medience Corporation for analysis.

Baseline, and after the 8-week intervention

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Krzesło do nauki: Tsuyoshi Takara, MD, Medical Corporation Seishinkai, Takara Clinic

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

8 grudnia 2025

Zakończenie podstawowe (Szacowany)

30 marca 2027

Ukończenie studiów (Szacowany)

30 kwietnia 2027

Daty rejestracji na studia

Pierwszy przesłany

21 stycznia 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

30 stycznia 2026

Pierwszy wysłany (Rzeczywisty)

6 lutego 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

30 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

29 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Inne numery identyfikacyjne badania

  • 01170-0018-29
  • UMIN000060011 (Identyfikator rejestru: UMIN-CTR)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

Data sharing will be discussed among the research affiliates after the study is completed.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj